Idylla™ EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients
Products are for professional/laboratory use only.
A recent publication of a large prospective study1 demonstrates the Idylla™ EGFR Mutation Test leads to
Products are for professional/laboratory use only.
A recent publication of a large prospective study1 demonstrates the Idylla™ EGFR Mutation Test leads to
Products are for professional/laboratory use only.
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US)
This study shows that Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods:
Products are for professional/laboratory use only.
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
Products are for professional/laboratory use only.
For patients with advanced lung cancer, the expected median survival is approximately one year however treatment with targeted tyrosine kinase inhibitor (TKI) therapy can improve outcomes for patients who have certain molecular alterations that can be identified by molecular testing1.
Products are for professional/laboratory use only.
ZytoVision’s ZytoLight® products are designed for the identification of genetic aberrations eg. translocations, deletions, amplifications and chromosomal aneuploidies by Fluorescence in situ Hybridisation (FISH) in formalin-fixed, paraffin-embedded tissue sections, cell samples, blood or bone marrow smears and metaphase chromosome spreads.
Products are for professional/laboratory use only.
A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).